Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 11/20 | 0.48 |
| ▸ | CA2 | P00918 | 11/20 | 0.48 |
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA9 | Q16790 | 6/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27207965 | 0.98 | TDP1 (0.59) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL6665327 | 0.95 | MEN1 (0.64) | MEN1KMT2AGAATDP1MAOA | |
| Hydrochloric Acid SCHEMBL6122869 | 0.94 | MEN1 (0.62) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL4624537 | 0.89 | MEN1 (0.54) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL4107078 | 0.88 | TDP1 (0.61) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL20364081 | 0.88 | MEN1 (0.58) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL6357111 | 0.88 | MEN1 (0.58) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL30915267 | 0.88 | TDP1 (0.61) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL4107080 | 0.88 | TDP1 (0.61) | MEN1KMT2AGAATDP1MAOA | |
| SCHEMBL7793993 | 0.85 | MEN1 (0.59) | MEN1KMT2AGAATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279233-A1 | MACROCYCLIC TAK1 INHIBITORS | AQILION AB (SE) | 2024-08-22 | — | — | US | disclosed |
| EP-4363422-A1 | MACROCYCLIC TAK1 INHIBITORS | Aqilion AB (SE) | 2024-05-08 | — | — | EP | disclosed |
| CN-117561262-A | Macrocyclic TAK1 inhibitors | 阿奎利恩有限公司 | 2024-02-13 | — | — | CN | disclosed |
| WO-2023275199-A1 | MACROCYCLIC TAK1 INHIBITORS | AQILION AB (SE) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023275199-A1 | MACROCYCLIC TAK1 INHIBITORS | AQILION AB (SE) | 2023-01-05 | — | — | WO | disclosed |
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7727991-B2 | Substituted melanocortin receptor-specific single acyl piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1922072-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | Palatin Technologies, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| WO-2007021990-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20060287330-A1 | Substituted Melanocortin Receptor-Specific Single Acyl Piperazine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-20060287331-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287330-A1 | Substituted Melanocortin Receptor-Specific Single Acyl Piperazine Compounds | MC4R, MC5R, MC3R | MEN1 2493/4885KMT2A 168/4885GAA 3817/4885 |
| US-20240279233-A1 | MACROCYCLIC TAK1 INHIBITORS | TAB1, TBK1, IRAK3 | MEN1 317/4885KMT2A 1921/4885GAA 3191/4885 |
| US-20060287331-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | MC4R, MC1R, MC5R | MEN1 1160/4885KMT2A 208/4885GAA 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.